• Thought Leadership

A Wealth of Healthcare Industry Insights

Explore our research, white papers, reports, briefs, and case studies—all based on QuintilesIMS's extensive market foresight, sophisticated analytics and technology leadership. Our global reach, local expertise and singular focus on the healthcare industry enables us to see patterns and connections that can be difficult to see. 

Featured Thought Leadership Report:

Global Oncology Trends 2017 - Advances, Complexity and Cost

Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine and immuno-oncology. In this report, we share our perspective on some of the trends observed in 2016, including impact on cancer outcomes, the redefinition of many cancers, availability and costs of oncology therapeutics and complexity in cancer treatments.

Read More 

QuintilesIMS Thought Leadership

  • Orphan Drugs in the United States

    09 Oct 2017

    Rare diseases are serious, chronic illnesses that can become progressively disabling and can limit life expectancy. In the United States, the National Institutes for Health estimates that between 25 million and 30 million people suffer from rare diseases – defined as those affecting fewer than 200,000 people. This report provides perspective on rare diseases and their treatments, including an in-depth analysis on orphan drug volume and pricing in the context of specialty therapies.

  • Understanding the Drivers of Drug Expenditure in the U.S.

    12 Sep 2017

    This report provides analysis around a key aspect of medicine spending growth trends: manufacturer net revenues.  It draws on previously published analysis in our reports Medicines Use and Spending in the U.S.: A Review of 2016 and Outlook to 2021 (April 2017) and Outlook for Global Medicines Through 2021: Balancing Cost and Value (Dec 2017).  

  • Understanding the Dynamics of Drug Expenditure: Shares, Levels, Compositions, and Drivers

    11 Jul 2017

    While the level of drug expenditure is closely watched and often commented upon, the composition of that expenditure and its dynamics are less well understood. In developed countries, including those analyzed in this report – France, Germany, Japan, U.K. and U.S. – the changes over the past 20 years have been dramatic in terms of the types of medicine, the diseases they are used to treat, and the specific molecules within a therapy class.

  • Economic Implications of Improving Type 2 Diabetes Management in China

    28 Jun 2017

    As the prevalence of type 2 diabetes increases globally, the condition and its associated complications are generating a considerable economic burden within healthcare systems. China reflects this trend—110 million people suffered from type 2 diabetes in 2015. That number is expected to grow to 151 million by 2040. The report assesses both the current and future economic burden of type 2 diabetes. It also quantifies possible cost savings and clinical improvements that can be expected from policy changes that improve the quality of diabetes management in China.

  • A Call to Action: Alzheimer’s Disease on the Threshold of Change

    13 Jun 2017

    Alzheimer’s Disease continues to be a common cause of death in elderly patients. To successfully address five critical challenges in this therapy area, pharma and biotech must adopt an 'act now' mentality, working together to make headway against this complex disease.

  • AccessPoint: 2017

    In this issue, we explore technology-driven breakthroughs and the new uses of evidence that are creating new possibilities for real-world evidence and real-world insights.

  • Global Oncology Trends 2017 - Advances, Complexity and Cost

    31 May 2017

    Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine and immuno-oncology. In this report, we share our perspective on some of the trends observed in 2016, including impact on cancer outcomes, the redefinition of many cancers, availability and costs of oncology therapeutics and complexity in cancer treatments.

  • Planning, Executing, and Monitoring The Three Pillars of an Effective Marketing Campaign

    29 May 2017

    This report examines the current state of marketing services within the pharmaceutical industry, what has brought us to this point, and the available solutions that may help pharma push beyond traditional marketing efforts and leverage today’s online and offline opportunities with the abilty to measure their impact.

  • Upholding the Clinical Promise of Precision Medicine Current Position and Outlook

    22 May 2017

    An understanding of systems biology has allowed for greater insight into the processes that govern disease and has helped to usher in the era of precision medicine—where the right patient gets the right therapy at the right dose and experiences the right response. This report provides key insights into the characterization of systems therapeutics and precision medicines. It also reports on their use and spending though 2016. The report introduces a framework for understanding the unique challenges associated with these therapies including cost, clinical decision making and the roles of healthcare stakeholders.

  • Medicines Use and Spending in the U.S. A Review of 2016 and Outlook to 2021

    04 May 2017

    In this report we highlight various aspects of the market for medicines in the U.S—spanning aggregate spending, key medicine categories, volumes, patient cost exposure, as well as our outlook to 2021. The report seeks to provide appropriate context and perspective around the complex factors that drive the level of spending on medicines and their role in our healthcare system.

  • Disruption and maturity: the next evolution of biologics

    30 Mar 2017

    Since the widespread commercialisation of the first recombinant protein, human insulin, biologic drugs have offered vast improvements in disease treatment and safety to high-need patients. This has driven their commercial success, biologics now representing half of the global top 20 drugs list, taking an increasing share of the market year on year.

  • acts 2016

    14 Mar 2017

    We’re proud to be publishing the 30th edition of the ACTS report, the QuintilesIMS Annual Report on Quality Assessment. This sustained effort demonstrates our strong commitment to meeting your information needs. As our valued customer, you depend upon having the right information at the right time in order to make effective decisions and react appropriately to rapidly changing markets.

  • Parallel trade: Which factors determine the flow of pharmaceuticals in Europe?

    06 Mar 2017

    Insights into the market segment of parallel imports as well as an outlook on the development of parallel trade. Focus: Germany and the United Kingdom after the Brexit decision.

  • Seizing the potential of commercial outsourcing in the pharmaceutical sector

    06 Mar 2017

    The power and potential of outsourcing has long been recognized as a core enabler of business growth. Yet while the pharmaceutical industry has been making strides in this area, there is still some way to go to realize the full potential; only in the past decade has the industry started to use outsourcing in downstream commercial functions – an area poised to reap the most benefit.

  • Pricing and Market Access Outlook 2017 Edition

    30 Jan 2017

    We are pleased to introduce the 2017 Pricing and Market Access Outlook. As we move forward with a new identity as QuintilesIMS, so too does our Outlook. Rather than waiting once a year to bring you our thoughts about evolutions in the industry, we will be having an ongoing dialogue about trends throughout the year. As part of this approach, you will notice a more streamlined Outlook focused specifically on our annual launch pricing and time to market access trends. Many of you have shared with us that this is a section you value and regularly reference in your day-to-day work. We look forward to continuing our conversation over the coming year.

  • Channel preference versus promotional reality

    12 Jan 2017

    In this new whitepaper we present our exclusive research on the stated channel preferences (for communications from pharmaceutical companies) of a wide range of different types of Health Care Professional, by country, across the US, major Europe, Japan and key emerging markets. To complete the picture, the data is then mapped against the reported interactions, by channel type, which these Healthcare professionals actually received in the same time period.

  • Lifetime Trends in Biopharmaceutical Innovation Recent Evidence and Implications

    10 Jan 2017

    This report profiles the new active substances (NASs) launched in the U.S. over the past 20 years and measures the length of a molecule’s lifetime from patent filing to launch and eventual patent expiry. It also explores the significant variations in this lifetime when viewed by molecule characteristics such as therapy area, orphan drug status, and the type of companies involved in the development and marketing.

  • Outlook for Global Medicines through 2021

    06 Dec 2016

    Medicines are advancing at an astonishing rate, as are the challenges in funding access to them for countries around the world faced with slowing economic growth and limited resources. In this report, we provide an outlook on the use of medicines and spending levels through 2021.  We also explore new medicines in late stage research and development pipeline, and discuss issues of pricing, access and national priorities sure to be a focus over the next five years.

  • Ensuring Essential Medicines Satisfy Priority Healthcare Needs of Populations

    17 Nov 2016

    This report looks at the current state and future direction of essential medicines on the World Health Organization’s Model Essential Medicines List, as well as approaches that health systems that include these essential medicines into their own lists can take to ensure EMs achieve their full potential benefit to populations. This study was conducted independently by the QuintilesIMS Institute with funding support from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

  • Connecting Insights

    20 Oct 2016

    This report explores how connecting disparate streams of data can create valuable insights that can make the difference in today’s biopharmaceutical marketplace. While these opportunities for connections exist across all disease and therapeutic areas, they may be most acutely needed in the complex and dynamic area of oncology. This report makes the case for the process by which a looming crisis in oncology can be averted, by applying the science—and art—of connecting healthcare insights.

  • Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates

    12 Oct 2016

    In recent years, the cost of medicines in the U.S. has been the subject of much public discussion due to its pricing process complexity. This report analyzes twelve high volume therapy classes in Medicare Part D, measures the costs for 30 days of therapy for branded medicines in each class, and estimates net cost to Part D plans and patients including estimates of negotiated discounts and rebates. This study was conducted independently by the QuintilesIMS Institute with funding support from the Pharmaceutical Research and Manufacturers of America (PhRMA).

  • Orchestrated Customer Engagement: Build Customer Trust & Loyalty Through More Effective Engagement

    26 Sep 2016

    Learn how to improve customer loyalty and achieve commercial goals with greater ease and efficiency by making Orchestrated Customer Engagement a strategic priority.

  • Comparison of Hepatitis C Treatment Costs

    20 Sep 2016

    This report examines the actual cost of Hepatitis C treatments across multiple countries, focusing on media reporting of net prices negotiated between manufacturers and intermediaries. It seeks to go beyond the typical examination of list prices that are often misleading. It also includes a country comparison of the infected population being treated for Hepatitis C. This study was conducted independently by the IMS Institute with funding support from the Pharmaceutical Care Management Association (PCMA).

  • Use of Opioid Recovery Medications

    20 Sep 2016

    An estimated 2.4 million individuals are living with an opioid use disorder, and most are not receiving treatment or not receiving the most effective care. The focus of this research is to understand the trends in utilization and healthcare payer mix of buprenorphine (a partial opioid agonist used to treat opioid addiction) medications  and their use nationally and by state.  This report has a particular focus on the extent to which buprenorphine is being funded under state-level Medicaid programs (either Fee For Service or Managed Medicaid). The study was conducted independently by the IMS Institute with funding support from Advocates for Opioid Recovery.

  • Advancing Value-Based Healthcare in Asia

    01 Sep 2016

    In this report we examine the shift in Asia, and globally, from supply-driven healthcare systems to value-based patient-centered healthcare systems.  This report introduces the concept of value-based healthcare and illustrates how real-world data-driven decision modelling approaches can improve disease management and support value-based clinical and policy decision-making in Asia, offering applications in diabetes and stroke as case examples. 

  • Strategic Management Review 2016

    02 Aug 2016

    In this 2016 review you will find a set of key insights together with our growth and value forecasts. The review includes five key videos featuring author Graham Lewis, VP Global Pharma Strategy, IMS Health.

  • When Small Becomes Big: The New Challenges of Orphan Drugs in Europe

    22 Jul 2016

    IMS Health forecasts that between 2013 and 2018, 94 percent of list price value growth will be in specialty medicines in Europe. Orphan drugs are on the leading edge of this specialty trend. 

  • Engage with Confidence: Managing Online Adverse Event Reporting

    14 Jul 2016

    The healthcare industry, and, specifically, consumer health companies, are waking up to the enormous potential offered by social media and other online data sources to make better informed decisions around brand, product development and commercialization.

  • Improving Type 2 Diabetes Therapy Adherence and Persistence Around the World

    12 Jul 2016

    In the six report series, the IMS Health Institute explores how to address unnecessary economic and societal costs associated with poor compliance and persistence to Type 2 diabetes therapy.

  • Nexxus Marketing Standard Connectors

    17 Jun 2016

    Data is a critical component for engagements with healthcare professionals (HCPs). This whitepaper explains how you can optimize customer engagements by gathering information from many different sources and incorporating it into marketing and sales systems.

  • IMPACT: Facilitating Shared Learning and Collaborative Action Research to Improve Cancer Care

    13 Jun 2016

    This report describes the rationales for the IMPACT initiative, lays out rapid advances in and challenges for effective cancer care in evolving health systems across countries, and suggests a dynamic shared learning and action research process to improve cancer care collaboratively.  It also serves to invite participation of additional stakeholders in shaping and advancing the IMPACT initiative.

  • Global Oncology Trend Report a Review of 2015 and Outlook to 2020

    02 Jun 2016

    In this report, we share our updated perspective on some of the trends we have observed in 2015, including new treatment options, availability of cancer treatments, costs of oncology therapeutics and supportive care drugs, distribution of cancer drugs, and some of the dynamics that are specific to the U.S. as well as an outlook to 2020. 

  • Medicines Use and Spending in the U.S. - A Review of 2015 and Outlook to 2020

    12 Apr 2016

    In this report, we highlight different aspects of the use of medicines in the U.S., spanning overall spending, key market segments, volumes, patient cost exposure, healthcare delivery changes as well as the outlook to 2020.

  • Delivering on the Potential of Biosimilar Medicines

    29 Mar 2016

    The purpose of this report is to describe the potential role for biosimilars and their contribution to healthcare systems; the risks for stakeholders to realize that full potential value; and the requirements for competitive functioning markets in order to capture the full value.

  • IMS PharmaDeals Review of 2015: Return of the mega-merger and a shift to early-stage dealmaking

    23 Mar 2016

    In an era of low sales growth, pharmaceutical companies have looked to M&A in attempt to maintain profit growth, and in 2015, we saw the return of the mega-merger. In this white paper, IMS PharmaDeals analyses the deal trends of 2015 for you.
  • The Essential European Revolution: Why Multichannel is Vital for Europe

    16 Mar 2016

    As companies with innovative and protected products look to Europe as a key market for growth, understanding European market nuances and tailoring a multichannel strategy to fit those markets will be essential for success.

  • Managing the Complexities of Incentive Compensation and Territory Management: How does your approach impact the quality of your plan results?

    10 Mar 2016

    In this paper, QuintilesIMS outlines the four core inputs to any incentive compensation program, reviews the impacts of each input, and identifies areas in which better processes can improve speed, accuracy, and results.
  • Parallel trade: Which factors determine the flow of goods in Europe?

    23 Feb 2016

    Insights into the market segment of parallel imports and exports as well as an outlook on the development of parallel trade with pharmaceuticals.

  • New Strategic Information and Technology Roles in Life Sciences Companies

    02 Feb 2016

    This report, produced by the IMS Institute for Healthcare Informatics in collaboration with Egon Zehnder, examines how life sciences CIOs are playing an increasingly strategic role delivering technological transformation, and assesses how far companies have already transformed using a proprietary Information and Technology Transformation Scoring (ITTS) framework.

  • Price Declines after Branded Medicines Lose Exclusivity in the U.S.

    27 Jan 2016

    The purpose of this healthcare brief is to document the changing price of medicines as generics enter the market. While the public discourse and debate are focused on the issue of rising drug costs, we take this opportunity to highlight the reduction in prices associated with the use of generic medicines.

  • Which way now for mid-sized European companies?

    22 Dec 2015

    This white paper analyses the predicament Europe’s mid-sized players find themselves in, and outlines what they need to do to avoid being caught in an evolutionary backwater.
  • Closing the Healthcare Gap: The Critical Role of Non-Identified Information

    03 Dec 2015

    The dramatic increase in the amount of digitized healthcare information being generated brings new opportunity to close the “healthcare gap” – the difference between today’s reality and what is possible from a clinical, patient and economic perspective.

  • Global Medicines Use in 2020: Outlook and Implications

    12 Nov 2015

    In this report, we provide an outlook on - and the implications of - the use of medicines and spending levels in 2020. We take a global view of the markets for all types of pharmaceuticals, including small and large molecules, brands and generics, those dispensed in retail pharmaceutics as well as those used in hospital or clinic settings.

  • Branded Medicine Price Increases and the Impact of Off-Invoice Discounts and Rebates

    11 Nov 2015

    The purpose of this healthcare brief is to draw specific attention to previously published research from the IMS Institute which highlights not only the visible aspects of price increases, but also the less visible off-invoice discounts, rebates, coupons, and other price concessions to payers that often substantially offset these changes in list price.

  • Three Myths of Multichannel Marketing

    26 Oct 2015

    This white paper discusses three myths that are frequently associated with multichannel marketing, myths that prevent organisations from committing to multichannel marketing fully and effectively.

  • Emergence and Impact of Pharmacy Deductibles: Implications for Patients in Commercial Health Plans

    24 Sep 2015

    The objective of this report is to bring forward insights on the extent to which pharmacy deductibles are becoming a more common aspect of health plan design, and the impact they have on patient behavior related to pharmaceutical use.

  • Patient Adoption of mHealth

    15 Sep 2015

    This report provides an update to the mHealth landscape analysis that was published by the IMS Institute for Healthcare Informatics in 2013. Over the past two years, there has been progress in understanding and addressing the barriers to more mainstream adoption of mHealth. However, for mHealth to fully contribute to improving the delivery of healthcare, further multi-stakeholder effort is required. 

  • The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective

    10 Jun 2015

    The purpose of this report is to understand current European market trends and to quantify the full scope of generic medicines’ contributions.

  • Developments in Cancer Treatments, Market Dynamics, Patient Access and Value: Global Oncology Trend Report 2015

    29 Apr 2015

    In this report, we share our updated perspective on the clinical landscape and what lies ahead; the dynamics of the market for oncology-related pharmaceuticals; and the current state of patient access to medicines and value considerations.

  • Understanding the Role and Use of Essential Medicines Lists

    17 Apr 2015

    The purpose of this report is to summarize how the Essential Medicines List has changed, describe how the list is used, and to provide considerations for future revision

  • Medicines Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014

    06 Apr 2015

    In this report we bring together several perspectives on 2014: total system spending on medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including retail prescription co-pays; and transformations in disease treatment resulting from newly approved medicines.

  • Impact of Cost-per-QALY Reimbursement Criteria on Access to Cancer Drugs

    10 Mar 2015

    The purpose of this report is to further the understanding of the impacts that alternative approaches to reimbursement decisions have on patient care.

  • Global Outlook for Medicines Through 2018

    13 Nov 2014

    In this report, we provide an outlook on the use of medicines and spending levels through 2018. We take a global view of the markets for all types of pharmaceuticals, including small and large molecules, brands and generics, those dispensed in retail pharmaceutics as well as those used in hospital or clinic settings.   

  • Understanding the Pharmaceutical Value Chain

    04 Nov 2014

    The purpose of this report is to advance the understanding of the pharmaceutical value chain - describing the elements of the medicine value chain, the quantifying price build up for specific areas and countries, and the diversity of approaches and costs associated with the value chain.

  • Assessing Biosimilar Uptake and Competition in European Markets

    10 Oct 2014

    This report summarizes the findings of a study undertaken by IMS Health to assess drivers of biosimilar uptake and to measure the impact of biosimilar competition in Europe.

  • Harbingers of Change in Healthcare: Implications for the Role and Use of Medicines

    10 Sep 2014

    This report is focused on ten “harbingers of change”—recent events that may be a threshold reached, a decision made or an action taken. We believe these events represent turning points that will have a significant long-term impact on the role or use of medicines in the future and will affect all healthcare stakeholders.

  • Bringing Healthy Living to Ageing Citizens: The Role of Technology

    04 Jun 2014

    This report raises awareness of the urgent need to find and apply new approaches to supporting the health of ageing populations.

  • Innovation in Cancer Care and Implications for Health Systems: Global Oncology Trend Report

    01 May 2014

    In this report, we bring together the most comprehensive review of current trends in the oncology market, the state of innovation in therapeutics, measures of the value of treating cancer, and pricing trends.

  • Medicine Use and Shifting Costs of Healthcare: A Review of the Use of Medicines in the U.S. in 2013

    08 Apr 2014

    This report provides the first view of total system spending on medicines for 2013, focusing on the utilization of key healthcare services, including physician office visits, hospitalizations and Emergency Room use. We also examine patient costs for medicines and the shift in the types of employer-provided insurance. 

  • Riding the Information Technology Wave in
    Life Sciences: Priorities, Pitfalls and Promise

    04 Mar 2014

    This report provides a view of how the current technology wave—defined in terms of cloud- based storage, new applications, systems integration, and embedded analytics—will be harnessed by life sciences companies in their commercialization activities and why this is necessary for these companies to succeed in bringing innovative diagnostic and treatment options to patients.

  • Patient Savings Program Use Analysis

    01 Feb 2014

    A large number and variety of patient savings programs have been established over the past twenty years by pharmaceutical manufacturers in an effort to reduce financial barriers to patients and enable them to receive the medicines prescribed to them by healthcare professionals. The purpose of this report is to summarize the findings of a study undertaken by IMS Health (funded by Pfizer, Inc.).

  • Engaging Patients Through Social Media

    09 Jan 2014

    This report reviews the impact of social media on the use of medicines, including the role that pharmaceutical manufacturers are playing in leveraging social media platforms as part of their business model.

  • Defeating India's Silent Killer: The Fight to Diagnose and Treat Cervical Cancer

    26 Nov 2013

    This study puts into perspective the key aspects pertaining to disease burden, screening, prevention, diagnosis and treatment of cervical cancer; and, to share learning's from other countries and provide our recommendations for effective control. 

  • The Global Use of Medicines: Outlook through 2017

    18 Nov 2013

    This report shares our latest forecasts for pharmaceutical use and related costs.

  • Patient Apps for Improved Healthcare: From Novelty to Mainstream

    29 Oct 2013

    This is the first study of its kind to look at the current state of consumer mobile apps in healthcare.

  • Impact of Patent Settlements on Drug Costs Estimation of Saving

    28 Jun 2013

    Generic drugs are now used to fill about 85 percent of all prescriptions dispensed in the U.S., saving consumers and the healthcare system nearly $4 billion every week. This study quantifies the impact of patent settlements and early generic market entry on drug costs, measured at the trade price level.

  • Understanding Healthcare Access in India

    09 Jun 2013

    Expanding healthcare access is a critical priority for the Government of India and the private sector. 

  • Avoidable Costs in U.S. Healthcare

    31 May 2013

    Avoidable costs of more than $200 billion are incurred each year in the U.S. healthcare system as a result of medicines not being used responsibly by patients and healthcare professionals, according to a new study by the IMS Institute.

  • Electronic Prescribing: Prevalence Within the Cholesterol Lowering Market

    07 May 2013

    This paper examines the current extent and intensity of retail e-prescribing.

  • Declining Medicine Use and Costs: For Better or Worse?

    20 Apr 2013

    As implementation of the Affordable Care Act brings fundamental change to healthcare access, delivery systems and payment structures, the landscape will continue to change in the next 5 years and beyond. 

  • Shift from Fee-for-Service to Managed Medicaid: What is the Impact on Patient Care?

    16 Mar 2013

    As states take on more responsibility with expanded Medicaid enrollment and management of exchanges in 2014, their direct and indirect impact on patient care will be subject to closer scrutiny.

  • Responsible Use of Medicines Report 2012

    22 Oct 2012

    The IMS Institute for Healthcare Informatics has identified an opportunity to save a half trillion dollars in annual global health spending through the responsible use of medicines.  

  • Key Findings from GPhA Study

    20 Aug 2012

    The Generic Pharmaceutical Association – GPhA – released its annual study showing cost savings generated by generic medicines in the United States. Murray Aitken, Executive Director, discusses key findings from the GPhA study and analysis conducted by the IMS Institute for Healthcare Informatics.

  • Transformations in Disease Treatment

    13 Aug 2012

    We continue the discussion of anticipated transformations in disease treatments through 2016 and offer additional perspective on new medicines that are expected to be launched over the next five years. We also highlight the gaps that are expected to remain in the treatment of several priority diseases, as identified in a 2004 report by the World Health Organization.

  • A Changing Landscape for Generics and Biosimilars

    23 Jul 2012

    An accelerated shift in spending for generics will occur in the next five years, increasing from $242 billion in 2011 to $224-244 billion by 2016, and impacting global spending on medicines. We discuss the changing landscape for generics and biosimilars from the IMS Institute’s new forecast.

  • Patient Sharing Among Physicians and Costs of Care: A Network Analytic Approach to Care Coordination Using Claims Data

    26 Jun 2012

    Improving care coordination is a national priority and a key focus of healthcare reforms. However, its measurement and ultimate achievement is challenging. Using the IMS LifeLink Health Plan Claims Database, this study, published in the Journal of General Internal Medicine, was designed to test whether patients whose providers frequently share patients with one another, "care density", tend to have lower costs of care and likelihood of hospitalization. Researchers found that patients treated by sets of physicians who share high numbers of patients tend to have lower costs.

  • Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes (T2DM)

    26 Jun 2012

    Intermittent “doses” of RT-CGM (unblinded use) were associated with a sustained reduction in A1C over 52 weeks as compared with daily self-monitoring of blood glucose (SMBG) (RT-CGM: -1.1% vs. SMBG: -0.5%) in patients with T2DM not on prandial insulin. This current analysis modeled the cost-effectiveness of RT-CGM for this type of intervention. Using the IMS CORE Diabetes Model, researchers projected the lifetime clinical and economic outcomes for RT-CGM vs. SMBG. The results show that RT-CGM is a cost-effective disease management option in the U.S. for people with T2DM not on prandial insulin. Repeated use of RT-CGM may result in additional cost-effective health benefits, due to longer-term impact on physiological parameters.

  • FDA Study Analyzes Medicine Use Within Pediatric Population

    18 Jun 2012

    Outpatient drug utilization among the U.S. pediatric population is not fully understood or widely characterized. We discuss a recent FDA study on the topic, and offer an IMS Institute analysis on prescription volume trends for antibiotic and ADHD medications in the U.S. pediatric population.

  • Lipitor’s Market Performance: Six Weeks Post Expiry

    16 Jun 2012

    News media has continued to report, almost weekly, about Lipitor following the drug’s loss of patent protection on November 30, 2011. We put in context Lipitor’s performance six weeks post-expiry, comparing it to the six-week post-expiry performance of other primary care medications with significant prescription volume that also faced generic competition in 2010 and 2011.

  • IMS Information Featured in Several Research Presentations at ASHECon

    11 Jun 2012

    At the 4th Biennial Conference of the American Society of Health Economists, several papers featuring IMS prescription data were presented. The conference, which featured 170 concurrent sessions with over 500 papers and 150 poster presentations on topics ranging from health policy to pharmaceutical innovation to economic disparity, is one of the preeminent events attended by health economists. We discuss the research presented.

  • Continuing Growth in Cancer Therapies

    04 Jun 2012

    ASCO, considered one of the largest medical professional events, has continued to serve as the showcase event for new therapies, research advances and innovation for combating cancer. We highlight global and U.S. spending for cancer treatments, noting that cancer therapies will remain the leading therapy class, both globally and in the United States.

  • Trends in Antihypertensives Use among Moroccan Patients

    31 May 2012

    Researchers analyzed consumption trends of antihypertensives in Morocco during the 1991–2010 period and the impacts after the institution of Mandatory Health Insurance and the marketing of generic drugs. Published in Pharmacoepidemiology and Drug Safety, researchers used IMS sales data in their analysis. They concluded that antihypertensive consumption increased between 1991 and 2010. However, despite the increase of generic drugs consumption, the levels of antihypertensive consumption remained lower than the needs of hypertensive patients.

  • Persistence and Compliance of Medications used in the Treatment of Osteoporosis - Analysis using a Large Scale, Representative, Longitudinal German Database

    31 May 2012

    Osteoporosis can be effectively treated with a number of medications. However, high persistence and compliance are required to assure efficacy. This retrospective analysis, published in the International Journal of Clinical Pharmacology and Therapeutics, examined persistence and compliance for a variety of medical interventions in Germany. The researchers utilized IMS LRx data; they concluded that persistence and compliance during the treatment of osteoporosis was found to be insufficient where treatment via an intravenous route and PTH showed the highest persistence and compliance rates, while daily oral bisphosphonates demonstrated lower persistence and compliance.

  • Explaining High Health Care Spending in the United States: An International Comparison of Supply, Utilization, Prices, and Quality

    31 May 2012

    This research, published in The Commonwealth Fund, used data from the Organization for Economic Cooperation and Development, IMS Health and other sources to compare healthcare spending, supply, utilization, prices, and quality in 13 industrialized countries. The researchers concluded that the U.S. spends far more on healthcare than any other country, and that higher spending is more likely due to higher prices and perhaps more readily accessible technology and greater obesity. Japan exhibited the lowest health spending, achieved primarily through aggressive price regulation.

  • Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 U.S. Claims Data Analysis

    31 May 2012

    Oral oncolytics are an increasingly important treatment option for cancer, and often fall within the pharmacy benefit, with the potential for increased out-of-pocket cost burden for patients. Researchers used the IMS LifeLink Health Plan Claims Database to evaluate patient out-of-pocket payments for oral oncolytic therapies in U.S. managed care plans. They concluded that among 21 oral oncolytics, average out-of-pocket costs ranged from $15 to >$500, and confirmed previous findings that showed wide differences among oral oncolytic options.  The study was published in the American Journal of Managed Care.

  • Update of the Evolution of Breast Cancer Incidence in Relation to Hormone Replacement Therapy use in Belgium and Review of Other Countries

    31 May 2012

    Belgium has one of the highest incidences of breast cancer in Europe and one of the highest rates of hormone replacement therapy (HRT) use. In this updated study, published in Maturitas, the researchers examined whether increased use of HRT led to reduced incidents of breast cancer. They used European standardized incidence rates for invasive breast cancer for patients age 50–69 years and IMS Health HRT sales data in the analysis. The researchers noted that, although this study is hampered by a number of limitations, these data support the idea that the drop in breast cancer incidence can be partly attributed to the decrease in HRT use.

  • Changes in Antipsychotic Use among Patients with Severe Mental Illness after a Food and Drug Administration Advisory

    30 May 2012

    A 2003 U.S. FDA advisory warned of increased hyperlipidemia and diabetes risk for patients taking second-generation antipsychotics (SGAs). Researchers examined subsequent changes in incident and prevalent SGA use among individuals with severe mental illness. They used IMS Health claims data, concluding that the metabolic risk advisory and the published consensus statement were associated with a selective reduction in olanzapine use without evidence of treatment disruptions among this population. The study was reported in the publication Pharmacoepidemiology and Drug Safety.

  • Valuing Real-World Evidence Post Launch

    28 May 2012

    IMS believes that we’ve reached a tipping point where taking an active role in RWE can help create a platform for building stronger stakeholder relationships and better inform healthcare decision making. We discuss the need to include real-world evidence in post-launch drug assessments and how regulatory bodies across the world are addressing RWE in their evaluations of new medicines.

  • A Retrospective Observational Single-Centre Study on the Burden of Immune Thrombocytopenia (ITP)

    25 May 2012

    German data on economic consequences of immune thrombocytopenia (ITP) are limited. Researchers from IMS Health and the University Hospital of Munich conducted a retrospective, observational study based on chart review of adult patients with a confirmed diagnosis of ITP at a German university hospital. They found that data concerning current healthcare provision for ITP patients in Germany indicate considerable resource consumption and the need for more effective treatment options in individual patients. The study was published in Onkologie.

  • Despite 2007 Law Requiring FDA Hotline to be Included in Print Drug Ads, Reporting of Adverse Events by Consumers Still Low

    26 Apr 2012

    In 2007, the federal government began requiring drug makers to include in their print direct-to-consumer advertisements information for consumers on how to contact the FDA directly to report any adverse events experienced after taking a prescription drug. In this Health Affairs article, researchers studied adverse event reports for 123 drugs before and after the enactment of the print advertising requirement and estimated that requirement’s impact with model simulations. They concluded that additional measures, such as more publicity about the Adverse Event Reporting System or more consumer education, should be considered to promote patient reporting of adverse events. The authors used IMS Health promotional spending data in their analysis.

  • Economic Outcomes of Exenatide versus Liraglutide in Type 2 Diabetes Patients in the United States: Results from a Retrospective Claims Database Analysis

    26 Apr 2012

    The safety and efficacy of the GLP-1 receptor agonists exenatide BID (exenatide) and liraglutide for treating type 2 diabetes mellitus (T2DM) have been established in clinical trials. This study, published in the Journal of Medical Economics, examined cost offsets and medication adherence for exenatide versus liraglutide in a large, managed care population in the United States. Using claims data from IMS Health, the researchers concluded patients initiating exenatide versus liraglutide for T2DM had similar medication adherence and total healthcare costs; however, exenatide patients had significantly lower total pharmacy costs.

  • Prevalence, Utilization, and Costs of Antiepileptic Drugs for Epilepsy in Germany—a Nationwide Population-Based Study in Children and Adults

    26 Apr 2012

    Nationwide analyses of drug use can provide a prevalence estimate of the underlying disease and can help in understanding the characteristics of treatment. This study, published in the Journal of Neurology, examined the utilization of antiepileptic drugs (AED) for epilepsy in Germany. Utilizing the IMS LRx database and IMS Disease Analyzer, researchers concluded that prevalence and prescribing patterns changed with age. Additionally, they noted that costs of AED against epilepsy added up to 1% of total medication costs in Germany.

  • Assessing Adherence-Based Quality Measures in Epilepsy

    26 Apr 2012

    The study, published in the International Journal for Quality in Health Care, aimed to examine the relationship of three alternative measures of adherence with seven negative outcomes associated with epilepsy for development of a quality measure in epilepsy. The design was a retrospective cohort analysis using the IMS LifeLink Health Plan Claims database.  For each definition of adherence, the odds ratios (ORs) comparing non-adherent with adherent groups were assessed for consistency and direction for the number of hospital admissions, emergency room (ER) visits, head injuries, including traumatic brain injuries, falls, motor vehicle accidents (MVAs), fractures and a "seizure" outcome defined as hospital admissions or ER visits with a primary diagnosis of epilepsy or convulsions.  The researchers concluded that the adherence measures defined non-adherent groups who were associated with negative outcomes in epilepsy.

  • Cost Comparison of Outpatient Treatment with Granulocyte Colony-Stimulating Factors in Germany

    26 Apr 2012

    Granulocyte colony-stimulating factors (G-CSF) are available for prevention of neutropenia and reduction of its complications in cytostatic chemotherapy.  This analysis, published in the International Journal of Clinical Pharmacology and Therapeutics, sought to determine the consumption rates for various G-CSF and to compare outpatient medication costs per patient and treatment cycle.  Using the IMS LRx database, prescription data of statutory health insurance members in Germany with G-CSF prescriptions between January 2008 and July 2010 were evaluated.  Treatment with the original preparation lenograstim was shown to be significantly cheaper compared to the other two original drugs and biosimilar, while the costs of G-CSF treatment with the original preparation lenograstim and the filgrastim biosimilars were in a similar range, but with a significantly lower cost for lenograstim.  Compared to their reference product, the biosimilars showed a cost advantage.

  • Treatment Cost of Invasive Fungal Disease in Patients with Acute Myelogenous Leukaemia or Myelodysplastic Syndrome in German Hospitals

    26 Apr 2012

    Invasive fungal disease (IFD) causes increasing morbidity and mortality in haematological cancer patients, and reliable cost data for treating IFD in German hospitals is not available.  The objective of the study, published in Mycoses, was to determine the institutional cost of treating the IFD.  Data were obtained by retrospective chart review in German hospitals. From the perspective of hospitals in Germany, the economic burden of IFD in patients with Acute Myelogenous Leukaemia or Myelodysplastic Syndrome is substantial, and prevention of IFD is necessary with respect to both clinical and economic reasons.

  • A Retrospective Database Analysis on Persistence with Inhaled Corticosteroid Therapy: Comparison of Two Dry Powder Inhalers During Asthma Treatment in Germany

    26 Apr 2012

    Asthma is one of the most common chronic diseases worldwide. Patient persistence with treatment is essential to achieve sufficient outcomes, in particular to avoid exacerbations.  The objective of the study, published in the International Journal of Clinical Pharmacology and Therapeutics, was to investigate inhaled corticosteroid (ICS) therapy with two different inhalers (Novolizer® and Turbuhaler®) by comparing persistence, concomitant use of additional asthma medication and occurrence of exacerbations in real life. Using the IMS Disease Analyzer, researches conducted a retrospective analysis of prescription data from outpatient treatment comparing treatment persistence of asthma patients using 200 μg budesonide either via Novopulmon®/Budecort® (Novolizer group = NOV) or Pulmicort® (Turbuhaler group = TUR). They found better therapy persistence with NOV compared to TUR during asthma treatment in Germany.

  • Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in Spain

    26 Apr 2012

    IMS researchers evaluated the cost-effectiveness of posaconazole compared with standard azole therapy (SAT; fluconazole or itraconazole) for the prevention of invasive fungal infections (IFI) and the reduction of overall mortality in high-risk neutropenic patients with acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS).  Posaconazole was associated with fewer IFI, increased life-years saved , and significantly lower costs, excluding costs of the underlying condition per patient relative to SAT.  Posaconazole was determined to be a cost-saving prophylactic strategy (lower costs and greater efficacy) compared with fluconazole or itraconazole in high-risk neutropenic patients.  The study was published in BMC Infectious Diseases.

  • Amputation Rate and Risk Factors in Type 2 Patients with Diabetic Foot Syndrome Under Real-life Conditions in Germany

    05 Apr 2012

    Complications related to diabetes can cause significant medical and economic burden on the health system and early therapeutic intervention is essential for patients with diabetic foot syndrome. In this study, published in Primary Care Diabetes, researchers analyzed the risk of amputation and the influencing factors for amputation for patients with type 2 diabetes that were suffering from diabetic foot syndrome. Using IMS Disease Analyzer, they concluded lower-limb amputations were independently associated with higher age, male gender, higher HbA1c value and longer diabetes duration but also some other diabetes complications.

  • The Burden of Illness of Osteoporosis in Canadian Men

    26 Mar 2012

    There is dearth of information about the burden of osteoporosis in Canadian men. To fill this gap, researchers conducted a burden of illness study aimed at estimating the economic burden attributable to osteoporosis in Canadian men aged 50 years and older.  They used the IMS Health Canadian Disease and Therapeutic Index survey and five national data sources to estimate healthcare resource utilization and costs associated with osteoporosis in men.  The study, published in the Journal of Bone and Mineral Research, revealed that male osteoporosis has a substantial economic burden on the Canadian society.

  • Clinical and Economic Outcomes in an Observational Study of COPD Maintenance Therapies: Multivariable Regression Versus Propensity Score Matching

    21 Mar 2012

    Randomized clinical trials (RCTs) have important limitations and, as a result, outcomes observed in RCTs cannot necessarily be generalized to the real world of clinical practice, where patients present with varying degrees of disease severity and a range of comorbidity profiles. In this study, researchers investigated equivalency of results from multivariable regression (MR) and propensity score matching (PSM) models using, as an example, a large study of chronic obstructive pulmonary disease (COPD) initial maintenance therapy. Utilizing the IMS LifeLink Health Claims database, the researchers concluded results from both methods were similar in direction and statistical significance, suggesting that MR and PSM were equivalent methods for mitigating bias. The research was published in the International Journal of Chronic Obstructive Pulmonary Disease.

  • The Impact of the Affordable Care Act on Health Spending

    21 Mar 2012

    Regardless of how the Supreme Court rules on the constitutionality of the Affordable Care Act, a number of reform provisions have already been implemented, or are underway, impacting spending and utilization of medicines in the U.S. Murray Aitken highlights how health reforms will positively impact the use of medicines as more Americans gain access to health insurance and prescription medications.

  • Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010

    21 Mar 2012

    Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, brand/generic distinctions, and in the practice of medicine contributes to ambiguous interpretations of pharmaceutical cost comparisons.  In this working report, with research support and analysis provided by the IMS Institute for Healthcare Informatics and IMS Health's MIDAS database, researchers sought to provide insights into cross-country pharmaceutical cost comparisons by focusing on eleven therapeutic classes that between 2004 and 2010 experienced patent expiration and loss of market exclusivity in eight industrialized countries.  They determined that five of the eleven classes experienced double-digit declines in daily costs, averaged over all countries: ace inhibitors (-19%), antinauseants (-14%), anti-ulcerants (-13%), calcium channel blockers (-12%) and lipid regulators (-11%), each of which experienced major patent expirations and generic entry.  The researchers noted that their research presents clear evidence on the downward evolution of prices and thus countries’ drug expenditures for therapeutic classes experiencing patent expiration over the 2004-2010, but future research needs to be done to assess how this evolution of costs has affected utilization.

  • Potential Cost-Effectiveness and Benefit-Cost Ratios of Adult Pneumococcal Vaccination in Germany

    21 Mar 2012

    Invasive and non-invasive Streptococcus pneumoniae infections in adults are associated with substantial morbidity, mortality and costs.  In Germany, Pneumococcal polysaccharide vaccination (PPV23) is recommended for all persons >60 years and for defined risk groups (age 5-59).  The aim of this study was to estimate the potential cost-effectiveness and benefit-cost ratios of the adult vaccination program (18 years and older), considering the launch of the pneumococcal conjugate vaccine for adults (PCV13).  Results showed that the health economic benefit of immunizing adults with PCV13 can be expected to outperform the sole use of PPV23, if the effectiveness of PCV13 is comparable to the effectiveness of PCV7.  The research was published in Health Economics Review.

  • Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs

    21 Mar 2012

    Chronic pain is known to be a significant and common health problem. Tapentadol, a recently developed centrally active, oral analgesic agent is used to treat adults with severe chronic pain that can be adequately managed only with opioid analgesics. This study, published in Clinical Therapeutics, compared the cost-effectiveness of tapentadol to that of opioids commonly used as first-line treatment of severe, chronic, nonmalignant pain from the perspective of the health care payer in Spain. Based on the findings from the present model, tapentadol was likely to be a cost-effective first-line treatment in patients with severe, chronic, nonmalignant pain in Spain according to the commonly accepted willingness-to-pay thresholds.

  • Budgetary Impact Analysis of Buprenorphine-Naloxone Combination (Suboxone®) in Spain

    21 Mar 2012

    Opioid addiction is a worldwide problem, and Methadone has been the most widely used agonist opioid treatment AOT.  However, buprenorphine, a partial mu-opiod agonist and a kappa-opiod antagonist, is fast gaining acceptance.  This study, published in Health Economics Review, sought to assess the budgetary impact in Spain of the introduction of buprenorphine-naloxone (B/N) combination. Using IMS MIDAS data, the researcher developed a budgetary impact model to estimate healthcare costs of the addition of B/N combination to the therapeutic arsenal for treating opioid dependent patients.  They determined that the addition of B/N combination would imply a maximum incremental yearly cost of Euros10.58 per patient compared to scenario only with methadone and would provide additional benefits.

  • Relative Risk of Acute Pancreatitis in Initiators of Exenatide Twice Daily Compared with other Anti-Diabetic Medication: a Follow-Up Study

    21 Mar 2012

    Previously, a retrospective cohort study found no increased risk of acute pancreatitis with current or recent use of exenatide twice daily compared with use of other anti-diabetic drugs. This follow-up study, investigated incident acute pancreatitis, with the use of a different data source and analytic method, in patients exposed to exenatide twice daily compared with patients exposed to other anti-diabetic medications. Published in Diabetic Medicine, the analysis used the IMS Health LifeLink Health Claims database which showed that exposure to exenatide twice daily was not associated with an increased risk of acute pancreatitis compared with exposure to other anti-diabetic medications.

  • Healthcare Spending: Inpatient Services

    19 Mar 2012

    For the privately insured population, facility-based services represent 84% of spending on inpatient services where members with chronic conditions driving the majority of expenditures. We continue our discussion on healthcare spending, focusing on patterns of spending and use for inpatient services among health plan members.

  • Antihypertensive Treatment and Risk of Dementia: a Retrospective Database Study

    05 Mar 2012

    Vascular risk factors play an important role in the pathogenesis of vascular dementia, as well as in Alzheimer’s disease, however the effect of antihypertensive medication on risk of dementia is unclear. Researchers aimed to investigate the association between antihypertensive prescriptions and incident dementia, using an IMS Health primary care database. The study, published in the International Journal of Clinical Pharmacology and Therapeutics, indicated a possible protective effect of some antihypertensive agents (betablockers, ACE-inhibitors) on the development of dementia and concluded that randomized controlled trials are required to confirm this finding.

  • Changes in Prescription Patterns before and after Reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Trial

    05 Mar 2012

    Recent trends suggest a decreased use of ezetimibe/simvastatin combination and coadministered ezetimibe plus statin therapies. This analysis, published in the Journal of Clinical Lipidology, evaluated changes in prescription patterns for ezetimibe/simvastatin, ezetimibe plus statins, and statin therapies and expected effects on low-density lipoprotein cholesterol (LDL-C) lowering during 2007 to 2008. The researchers patient-level data from the IMS Health Longitudinal Rx database six months before and after reporting of the results of The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) trial on Jan.14, 2008.  Their analysis showed that more patients switched from ezetimibe/simvastatin and ezetimibe plus statin to statin monotherapy six months after the reporting of the ENHANCE trial.

  • Anticancer Drug Development from Traditional Cytotoxic to Targeted Therapies: Evidence of Shorter Drug Research and Development Time, and Shorter Drug Lag in Japan

    05 Mar 2012

    Concern about the drug lag, the delay in marketing approval between one country and another, for anticancer drugs has increased in Japan. Researchers sought to investigate the current trend in oncology drug lag between the U.S. and Japan and identify oncology drugs approved in only one of the two countries, concluding that the emergence of new molecularly targeted agents has contributed to reducing the approval lag, most likely due to improvements in R&D strategy. In their analysis, published in the Journal of Clinical Pharmacy and Therapeutic, researchers used IMS MIDAS data.

  • Pharmaceutical Patents and Prices of Generics in Morocco and Neighboring Economies

    05 Mar 2012

    The importance of generics in relation to the need to enlarge access to pharmaceuticals in Morocco and its neighbor countries was profiled in this paper that appeared in the Journal of World Intellectual Property.  The attained results demonstrated the effective price decrease of generics relative to the originator drug, as well as a reduction the prices of the originals, as a means to enlarge access to medicines.

  • Healthcare Spending: A Look at the Top 1% Privately Insured

    27 Feb 2012

    We highlight the newest report from the IMS Institute, Healthcare Spending Among Privately Insured Individuals Under Age 65, which uses comprehensive, proprietary de-identified data to examine the cost drivers, member characteristics and healthcare utilization trends of private health plan members.

  • The U.S. Generic Landscape and Growth of Biosimilars

    21 Feb 2012

    We offer additional perspective on the future of generic medicines and the commercial landscape for biosimilars, which were two critical areas of discussion during the Generic Pharmaceutical Association annual meeting in February.

  • Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 2000–2010

    15 Feb 2012

    Health researchers sought to quantify the changes in the diagnosis of ADHD and its pharmacologic treatment, from 2000 through 2010, as a result of several recent clinical and regulatory changes for these medications in the United States. Using the IMS National Disease and Therapeutic Index, they examined aggregate trends among children and adolescents under 18 years of age to measure how diagnosis and treatment patterns have evolved. The research, published in Academic Pediatrics, demonstrated that the number of physician outpatient visits where ADHD was diagnosed increased 66 percent, from 6.2 million to 10.4 million, over the 10 year period, but concluded that the effects of these changing treatment patterns on children’s health outcomes and their families were unknown.

  • Adjusting For Risk Selection In State Health Insurance Exchanges Will Be Critically Important And Feasible, But Not Easy

    14 Feb 2012

    The viability and success of state-level health exchanges will require effective risk-adjustment strategies to compensate for differences in enrollees’ health status across health plans. For this Health Affairs article, the authors performed a simulation to show that under the premium rating restrictions in the law, large incentives for insurers to attract healthier enrollees will be likely to persist—resulting in substantial overpayment to plans with very healthy enrollees and underpayment to plans with very sick members. Using the IMS LifeLink Health Plans Claims Database, they concluded that risk adjustment based on patients’ diagnoses will yield paymooents to insurers that will be more accurate than what will come solely from the age-adjusted and other ratings allowed by the Affordable Care Act.

  • Canadian Guidelines for Rhinosinusitis: Practical Tools for the Busy Clinician

    13 Feb 2012

    Acute bacterial rhinosinusitis (ABRS) and chronic rhinosinusitis (CRS) frequently present in clinical practice; however, because ABRS and CRS have different pathologies and management strategies it is critical that clinicians understand the differences so appropriate treatment can be started. Published in BMC Ear, Nose and Throat Disorders, the authors discuss current Canadian guidelines for treating Rhinosinusitis, using the IMS Canadian Disease and Therapeutic Index to show that prescribing habits were nearly identical for patients with ABRS and for those with CRS. They noted that as the knowledge base of ABRS and CRS pathology and management continues to grow and evolve, physicians who desire to understand the current state of the pathologies and treatment approaches for ABRS and CRS, as well as their patients, will benefit from these guidelines.

  • IMS Ranks the Top 100 Integrated Health Networks

    06 Feb 2012

    Changes in the U.S. healthcare delivery system are upon us, and integrated health systems – whether they are termed ACOs, Integrated Delivery Networks, or Integrated Health Networks –all seek to improve health outcomes at lower cost by operating effectively as an integrated unit. Understanding the performance level and degree of integration is important to the evolving structure of our healthcare system. We highlight the IMS rankings and discuss our key findings.

  • State Medicaid Programs Did Not Make Use of Prior Authorization to Promote Safer Prescribing After Rosiglitizone Warning

    27 Jan 2012

    Preferred drug lists are used by state Medicaid programs help to limit prescribing of high-cost medicines and free providers from having to obtain prior authorization for a given prescription. For this Health Affairs article, researchers conducted a retrospective cohort study related to the FDA’s May 2007 safety warning regarding rosiglitizone (Avandia) to determine the impact of this warning on the drug’s availability on state Medicaid preferred drug lists and on the prescribing of diabetes medications to Medicaid beneficiaries. They found that state Medicaid programs missed important opportunities to promote safer, more effective prescribing following the safety warning. The researchers used IMS Health Xponent data to conduct their study.

  • Cost-Effectiveness Analysis on Pioglitazone Add-On Therapy to Patients Failing Insulin

    27 Jan 2012

    This study modeled long-term effects of adding pioglitazone to insulin in type 2 diabetes mellitus patients in Germany. Using the IMS Core Diabetes Model, the researchers examined how pioglitazone plus insulin treatment affected quality-adjusted life expectancy for patients and if higher drug acquisition costs of the combination treatment could partly be offset by decreases in complications. They found the addition of pioglitazone to insulin treatment was projected to be highly cost-effective in the German setting when compared to insulin from a healthcare payer perspective. The study was published in Gesundheitsökonomie.

  • The Association Between Leukotriene-Modifying Agents and Spontaneously Reported Suicide

    14 Jan 2012

    Suicide is a significant public health issue. This study, published in the Drug Information Journal, examined the association between leukotriene-modifying agents (LTMAs) and completed suicide. The researchers used IMS Xponent and FDA Adverse Event Reporting System data from 1999 to 2009. They found that rates of reported completed suicides associated with montelukast increased substantially following warnings issued by the FDA.

  • Trends in Neutropenia-Related Inpatient Events

    14 Jan 2012

    Neutropenic complications after myelosuppressive chemotherapy are associated with significant morbidity and mortality. Researchers conducted a cross-sectional analysis to study trends in neutropenia-related events. They used  hospital discharge data for patients with various cancers from 1989 to 2007 and IMS drug distribution data to estimate growth factors and myelosuppressive chemotherapy from 1994 to 2008. Published in the Journal of Oncology Practice, the researchers concluded that while the  number of hospitalizations with cancer diagnoses had remained steady since 1989, hospitalizations for neutropenic complications increased approximately two-fold from 1989 to 1997 before stabilizing.

  • Variation of Healthcare Resource Utilization According to GERD-associated Complications

    14 Jan 2012

    The impact of gastroesophageal reflux disease (GERD) associated complications on healthcare utilization can include many symptoms and deserves further evaluation. In this study, published in Diseases of the Esophagus, researchers used the IMS LifeLink Health Plan Claims Database to identify commercial insurance enrollees, age 18 to 75 years, with claims for GERD, and subsequent usage of proton pump inhibitors from Jan. 1, 2005 to Jun. 30, 2009. They compared patient characteristics, healthcare utilization, and costs between stage A and each stage with complicated GERD (B–D). They found that compared with stage A, all other cohorts had significantly higher all-cause and GERD-related costs, and determined that, while patients with more severe GERD represented a relatively small portion of the GERD cohort, these patients demonstrated significantly greater healthcare costs and overall utilization than patients with uncomplicated GERD.

  • Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 1998–2009

    14 Jan 2012

    The authors examined trends in the use of second-generation antipsychotics for treatment of bipolar disorder before and after the US FDA’s approval in 2000 of olanzapine for use in treating acute manic episodes of bipolar disorder. Using IMS Health National Disease and Therapeutic Index, the researchers derived monthly patient treatment visits between January 1998 and December 2009 by individuals 18 and older with a diagnosis of bipolar disorder who were treated with one or more pharmacotherapies. They concluded that second-generation antipsychotics are increasingly used for bipolar disorder, and their effectiveness compared with therapeutic alternatives merits further research. The study was published in Psychiatric Services.

  • Cost Analysis: Treatment of Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents in Five European Countries

    14 Jan 2012

    Researchers evaluated the cost-effectiveness of darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-beta (EPO-B) for treatment of chemotherapy-induced anemia in Belgium, extending the analysis to Austria, France, Italy, Portugal and Spain. They found that, in all countries, total and anemia-related costs were lowest in patients receiving DARB versus EPO-A or EPO-B, noting their findings could be valuable in healthcare decision-making in oncology patients treated in each of the countries studied. The researchers used IMS Health sales data in their analysis, which was published in the Journal of Medical Economics.

See More

Interested in learning more about how QuintilesIMS's Thought Leadership can help you succeed? Let us know how we can help you: